Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker Analyses by Cloughesy, Timothy et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study
of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in
Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte
Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker
Analyses
Cloughesy, Timothy; Finocchiaro, Gaetano; Belda-Iniesta, Cristóbal; Recht, Lawrence; Brandes, Alba
A; Pineda, Estela; Mikkelsen, Tom; Chinot, Olivier L; Balana, Carmen; Macdonald, David R; Westphal,
Manfred; Hopkins, Kirsten; Weller, Michael; Bais, Carlos; Sandmann, Thomas; Bruey, Jean-Marie;
Koeppen, Hartmut; Liu, Bo; Verret, Wendy; Phan, See-Chun; Shames, David S
DOI: https://doi.org/10.1200/JCO.2015.64.7685
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-141041
Published Version
Originally published at:
Cloughesy, Timothy; Finocchiaro, Gaetano; Belda-Iniesta, Cristóbal; Recht, Lawrence; Brandes, Alba A;
Pineda, Estela; Mikkelsen, Tom; Chinot, Olivier L; Balana, Carmen; Macdonald, David R; Westphal,
Manfred; Hopkins, Kirsten; Weller, Michael; Bais, Carlos; Sandmann, Thomas; Bruey, Jean-Marie;
Koeppen, Hartmut; Liu, Bo; Verret, Wendy; Phan, See-Chun; Shames, David S (2017). Randomized,
Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus
Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte
Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker Analyses. Journal of Clinical
Oncology, 35(3):343-351.
DOI: https://doi.org/10.1200/JCO.2015.64.7685
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
Randomized, Double-Blind, Placebo-Controlled, Multicenter
Phase II Study of Onartuzumab Plus Bevacizumab Versus
Placebo Plus Bevacizumab in Patients With Recurrent
Glioblastoma: Efﬁcacy, Safety, and Hepatocyte Growth Factor
and O6-Methylguanine–DNA Methyltransferase
Biomarker Analyses
Timothy Cloughesy, Gaetano Finocchiaro, Cristo´bal Belda-Iniesta, Lawrence Recht, Alba A. Brandes,
Estela Pineda, Tom Mikkelsen, Olivier L. Chinot, Carmen Balana, David R. Macdonald, Manfred Westphal,
Kirsten Hopkins, Michael Weller, Carlos Bais, Thomas Sandmann, Jean-Marie Bruey, Hartmut Koeppen, Bo Liu,
Wendy Verret, See-Chun Phan, and David S. Shames
A B S T R A C T
Purpose
Bevacizumab regimens are approved for the treatment of recurrent glioblastoma in many countries.
Aberrant mesenchymal-epithelial transition factor (MET) expression has been reported in glio-
blastoma and may contribute to bevacizumab resistance. The phase II study GO27819 investigated
the monovalent MET inhibitor onartuzumab plus bevacizumab (Ona + Bev) versus placebo plus
bevacizumab (Pla + Bev) in recurrent glioblastoma.
Methods
At ﬁrst recurrence after chemoradiation, bevacizumab-naı¨ve patients with glioblastoma were ran-
domly assigned 1:1 to receive Ona (15 mg/kg, once every 3 weeks) + Bev (15 mg/kg, once every
3weeks) or Pla + Bev until disease progression. The primary end point was progression-free survival
by response assessment in neuro-oncology criteria. Secondary end points were overall survival,
objective response rate, duration of response, and safety. Exploratory biomarker analyses correlated
efﬁcacy with expression levels of MET ligand hepatocyte growth factor, O6-methylguanine–DNA
methyltransferase promoter methylation, and glioblastoma subtype.
Results
Among 129 patients enrolled (Ona + Bev, n = 64; Pla + Bev, n = 65), baseline characteristics were
balanced. The median progression-free survival was 3.9 months for Ona + Bev versus 2.9 months
for Pla + Bev (hazard ratio, 1.06; 95% CI, 0.72 to 1.56; P = .7444). The median overall survival was
8.8 months for Ona + Bev and 12.6 months for Pla + Bev (hazard ratio, 1.45; 95% CI, 0.88 to 2.37;
P = .1389). Grade$ 3 adverse events were reported in 38.5% of patients who received Ona + Bev
and 35.9% of patients who received Pla + Bev. Exploratory biomarker analyses suggested that
patients with high expression of hepatocyte growth factor or unmethylated O6-methylguanine–DNA
methyltransferase may beneﬁt from Ona + Bev.
Conclusion
There was no evidence of further clinical beneﬁt with the addition of onartuzumab to bevacizumab
compared with bevacizumab plus placebo in unselected patients with recurrent glioblastoma in this
phase II study; however, further investigation into biomarker subgroups is warranted.
J Clin Oncol 35:343-351. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Standard treatment of newly diagnosed glio-
blastoma (the most common primary tumor in
the CNS1,2) is surgical debulking followed by
radiotherapy and temozolomide, providing a
median overall survival (OS) of 14.6 months.3,4
Recent data suggest that glioblastoma comprises
clinically relevant subtypes (proneural, mes-
enchymal, and proliferative/neural) that exhibit
different prognostic outcomes and treatment
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responses.5 Prognostic beneﬁts have been reported for mesen-
chymal and neural subtypes, unlike proneural subtypes.5
Glioblastomas are highly vascularized tumors6 and respond to
antiangiogenic agents.7-13 The Avastin in Glioblastoma (AVAglio)
and RTOG-0825 studies evaluated ﬁrst-line radiotherapy, temo-
zolomide, and either bevacizumab or placebo in newly diagnosed
gliomas; AVAglio reported median progression-free survival (PFS)
of 10.6 versus 6.2 months, respectively,14 and RTOG-0825 reported
median PFS of 10.7 versus 7.3 months, respectively.15 However,
neither study demonstrated an OS beneﬁt for the bevacizumab-
containing regimen. A retrospective subgroup analysis of AVAglio
reported that mesenchymal and proneural subtypes derived PFS
beneﬁt with the bevacizumab combination; however, only the
proneural subtype reported a survival beneﬁt.16
The mesenchymal-epithelial transition factor (MET) pathway
can promote proliferation, survival, and metastasis in tumors and
can be dysregulated by MET receptor mutations or ampliﬁca-
tion, and overexpression of its ligand, hepatocyte growth factor
(HGF).17 Murine models suggest that the MET pathway may lead
to resistance in glioblastomas receiving antiangiogenic therapy.18
Glioblastomas can express MET as assessed by immunohisto-
chemistry (IHC)19,20; approximately 88% have aberrant down-
stream MET signaling, and 4% have MET ampliﬁcation.21
Expression of HGF is also seen in glioblastomas.21,22 Onartuzu-
mab, a humanized, monovalent monoclonal anti-MET antibody,
demonstrated inhibition of glioblastoma growth in preclini-
cal testing.23 Therefore, the MET pathway is a rational target
to investigate in glioblastoma. The phase II GO27819 study
(NCT01632228) investigated the safety and efﬁcacy of onartuzu-
mab plus bevacizumab versus placebo plus bevacizumab in re-
current glioblastoma.
PATIENTS AND METHODS
At ﬁrst recurrence after chemoradiation, bevacizumab-naı¨ve patients
with glioblastoma were randomly assigned 1:1 by interactive voice/Web
response system to receive intravenous onartuzumab (15 mg/kg) plus
bevacizumab (15 mg/kg; Ona + Bev) or placebo plus bevacizumab (Pla +
Bev) in 3-weekly cycles (day 1) until disease progression. Enrollment in
a Pla + Ona arm was put on hold during an initial safety assessment and
was subsequently closed as a result of concerns regarding unequal ran-
domization. Patients were stratiﬁed by age (, 50 years v $ 50 years) and
Karnofsky performance status (70% to 80% v 90% to 100%).
To meet inclusion criteria, patients had to be at least 18 years old with
Karnofsky performance status $ 70%; with histologically conﬁrmed
glioblastoma at ﬁrst recurrence (by Response Assessment in Neuro-
Oncology criteria24) after concurrent or adjuvant chemoradiotherapy (no
more than one previous temozolomide-based regimen; no previous
therapy targeting angiogenic or MET pathways). Prior therapy with
Gamma Knife or focal high-dose radiotherapy was allowed if histologic
recurrence was documented.
Patients were excluded if they were unable to undergo brain magnetic
resonance imaging scans with intravenous gadolinium. Patients with
absolute neutrophil count , 1.5 3 109/L, platelet count , 100 3 109/L,
hemoglobin , 9.0 g/dL, total bilirubin $ 1.5 3 upper limit of normal,
serum creatinine . 1.5 3 upper limit of normal, calculated creatinine
clearance , 60 mL/min, or urine dip-stick test for proteinuria $ 2+ were
also excluded. Patients who had prior treatment with prolifeprospan 20
carmustine wafer or a prior intracerebral agent were excluded. Patients
with inadequately controlled hypertension or diabetes, history of
hypertensive crisis, hypertensive encephalopathy, or signiﬁcant vascular
disease were not included. Patients with evidence of bleeding diathesis or
coagulopathy, history of abdominal ﬁstula, GI perforation or intracranial
abscess within 6 months before random assignment, or history of another
malignancy in the previous 3 years (with a disease-free interval of , 3
years) were also excluded, as were those with serious nonhealing wounds,
active ulcers, or untreated bone fractures.
Parafﬁn-embedded tumor samples were required to determine MET
IHC expression status.25 Tissue from recurrent surgery was preferred, but
tissue from the initial surgery was sufﬁcient for study entry. MET-positive
status was initially deﬁned as$ 50% of tumor cells with membrane and/or
cytoplasmic staining at moderate-to-high intensity. An exploratory MET-
positive status cutoff of $ 10% was also evaluated.
HGF RNA expression was assessed by cobas polymerase chain re-
action (PCR; Roche Molecular Systems, Pleasanton, CA), with high ex-
pression classed as the upper 25% subgroup and low expression as the
lower 75% subgroup on the basis of analysis of the Subpopulation
Treatment Effect Pattern Plots (Appendix Fig A1, online only). HGF
expression was also evaluated by nonisotopic in situ hybridization (ISH)
using branched DNA technology (Advanced Cell Diagnostics, Hayward,
CA; Appendix Fig A2, online only). Promoter methylation of DNA repair
gene O6-methylguanine–DNA methyltransferase (MGMT), a potential
positive prognostic marker for glioblastomas,26 was also evaluated by
quantitative methylation-speciﬁc PCR.27 Retrospective analyses of AVAglio
indicated that glioblastoma subtypes were differentially associated with
bevacizumab efﬁcacy16; therefore, in this analysis, correlation between
glioblastoma subtype determined by NanoString gene expression and
efﬁcacy was assessed (Appendix, online only).
The coprimary end points were PFS by Response Assessment in Neuro-
Oncology criteria in the intent-to-treat (ITT) population and the MET-
positive subpopulation. Secondary end points (for ITT and MET
biomarker–positive subgroups) included median OS, 9-month OS rate, 6-
month PFS rate, overall response rate (ORR), duration of response, and safety.
PFS andOSwere assessed using the Kaplan-Meier method. P values of Ona +
Bev versus Pla + Bev were obtained from either the log-rank test or the Cox
model, and hazard ratios (HRs) were estimated from the Cox model. The
biomarker effect was further evaluated using the multivariable Cox model,
including the treatment, biomarker, their interaction, and baseline charac-
teristics. Statistical signiﬁcance was set at .05 (two-sided signiﬁcance). Safety
was assessed per National Cancer Institute Common Terminology Criteria for
Adverse Events version 4.0. The study was conducted in 42 centers across
eight countries, in accordance with the Declaration of Helsinki and Good
Clinical Practice principles; patients provided written informed consent.
RESULTS
Patients
Between June 2012 and February 2013, 64 patients were
randomly assigned to Ona + Bev and 65 to Pla + Bev. Patient
disposition is shown in Fig 1. The clinical data cutoff was No-
vember 7, 2013. The median follow-up was 9.8 and 9.9 months,
respectively, for Ona + Bev and Pla + Bev. At the clinical cutoff, 59
patients receiving Ona + Bev (92%) and 55 patients receiving Pla +
Bev (85%) had stopped study treatment (Fig 1).
Baseline characteristics were balanced between the arms
(Table 1). Most patients (91.5%) had tumors with low MET ex-
pression (MET IHC score 0, 1+; IHC 50% staining cutoff). For the
10% staining cutoff, 79.8% of tumors were MET negative. Because
only ﬁve patients across the arms had MET-positive tumors by the
50% staining cutoff, this sample was deemed too small to produce
meaningful results; therefore, the planned analyses in this sub-
group were cancelled.
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Efficacy
The median PFS (ITT) was 3.9 months for Ona + Bev and
2.9 months for Pla + Bev (HR, 1.06; 95% CI, 0.72 to 1.56;
P = .7444; Fig 2A). Subgroup analyses of PFS were consistent with
ITT data (Fig 2B). The median OS was 8.8 months for Ona + Bev
and 12.6 months for Pla + Bev (HR, 1.45; 95% CI, 0.88 to 2.37;
P = .1389; Fig 2C). Predeﬁned subgroup analyses of OS were
generally consistent with ITT results (Fig 2D). The 6-month PFS
rate was 33.9% for Ona + Bev and 29.0% for Pla + Bev (P = .5555).
The 9-month OS rates were 49.7% and 57.2%, respectively, for
Ona + Bev and Pla + Bev (P = .4115). The ORR was 22.2% in the
Ona + Bev arm (12 of 54 patients; one complete response) and
23.7% in the Pla + Bev arm (14 of 59 patients; three complete
responses). The median duration of response was 6.4 months for
Ona + Bev and 9.7 months for Pla + Bev.
Exploratory Biomarker Analysis
Glioblastoma subtype. Recent retrospective analysis from
AVAglio indicated that glioblastoma subtypes were differentially
associated with outcomes to bevacizumab16; therefore, glioblas-
toma subtype was evaluated in GO27819. There were pro-
portionally more mesenchymal-subtype tumors (47% v 41%,
respectively) and fewer proneural tumors (23.5% v 30.3%,
respectively) in the GO27819 study than in AVAglio. The results
showed that there was no difference in PFS between the mesen-
chymal subtype compared with other subtypes in GO27819
(Appendix Fig A3, online only).
Because MET/HGF signaling is essential in maintaining the
mesenchymal phenotype, the association between HGF expression
and glioblastoma subtype was analyzed in AVAglio and GO27819
using NanoString technology.16 As expected, HGF expression
was associated with the mesenchymal phenotype in both studies,
suggesting that this may be a common occurrence in glioblastoma
biology (Appendix Tables A1 to A3, online only).
HGF Analysis
Analysis of HGF expression in the AVAglio study showed no
signiﬁcant differences in PFS (HR, 1.25; P = .24) or OS (HR, 1.11;
P = .57) for high expression of HGF versus low expression of HGF
in the control arm; however, low expression of HGF seemed to be
predictive of improved efﬁcacy for bevacizumab (PFS: HR, 1.71;
P = .0056; OS: HR, 1.56; P = .027; Appendix Fig A4, online only).
Therefore, it was decided to correlate HGF expression with efﬁcacy
in GO27819.
In GO27819, 119 patients (Ona + Bev, n = 58; Pla + Bev,
n = 61) had PCR results for HGF available. In the Pla + Bev arm,
patients with high HGF expression (upper 25%, n = 16) had
shorter efﬁcacy outcomes than those with lower PCR levels ofHGF
(lower 75%, n = 45) for PFS (median PFS: 2.8 v 4.1 months,
respectively; HR, 1.67; 95% CI, 0.90 to 3.13; P = .1167) and OS
(median OS: 7.3 months for the upper 25% group and not reached
[NR] for the lower 75% group; HR, 1.65; 95% CI, 0.76 to 3.59;
P = .2012); however, the differences were not statistically signiﬁcant.
In patients with PCR expression of HGF in the upper 25%
subgroup (Ona + Bev, n = 14; Pla + Bev, n = 16), signiﬁcantly longer
median PFS was seen with Ona + Bev (6.1 months) versus Pla + Bev
(2.8 months; HR, 0.37; 95% CI, 0.16 to 0.86; P = .0201; Fig 3A). The
median OS was longer with Ona + Bev in this subgroup (NR for
Ona + Bev v 7.3 months for Pla + Bev; HR, 0.29; 95% CI, 0.08 to
1.06; P = .0604; Fig 3B). Patients in the upper 25% subgroup of PCR
Pla + Bev
ITT
(n = 65; 100%)
Received study treatment 
(n = 65; 100%)
Continuing study
treatment at clinical
cut off
(n = 10; 15%)
Ona + Bev
ITT
(n = 64; 100%)
Received study treatment 
(n = 64; 100%)
Continuing study
treatment at clinical
cut off
(n = 5; 8%)
No study treatment
(n = 0)
Study treatment stopped
(n= 55; 85%)
AE (n = 3; 4.6%)
Death (n = 0; 0%)
Other (n = 1; 1.5%)
PD (n = 51; 78.5%)
Patient choice (n = 0; 0%)
Randomly assigned 
(N = 129)
No study treatment
(n = 0)
Study treatment stopped
(n= 59; 92%)
AE (n= 7; 10.9%)
Death (n = 2; 3.1%)
Other (n = 1; 1.6%)
PD (n = 45; 70.3%)
Patient choice (n = 4; 6.3%)
Fig 1. CONSORT diagram. Patient disposition.
AE, adverse event; ITT, intent to treat; Ona +Bev,
onartuzumab plus bevacizumab; PD, progressive
disease; Pla + Bev, placebo plus bevacizumab.
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expression of HGF also had signiﬁcantly higher ORR with Ona +
Bev compared with Pla + Bev (35.7% v 0%; P = .014).
Among patients with PCR expression of HGF in the lower
75% subgroup, those treated with Ona + Bev (n = 44) had shorter
median PFS (2.8 v 4.1 months, respectively; HR, 1.39; 95% CI, 0.87
to 2.20; P = .1589) and signiﬁcantly shorter OS (8.6 months v NR,
respectively; HR, 1.86; 95% CI, 1.03 to 3.36; P = .0381) compared
with those treated with Pla + Bev (n = 45; Fig 3C and D).
HGF expression was also assessed by ISH in GO27819 and
correlated with PFS and OS results (Appendix Fig A5, online only).
The overlap of high versus lowHGF expression as assessed by PCR
versus ISH is shown in Appendix Table A4 (online only).
Although themesenchymal subtype did not predict outcomes,
HGF levels seemed to be predictive of Ona + Bev efﬁcacy. To
evaluate this, we compared outcomes for themesenchymal subtype
or other subtypes stratiﬁed by HGF expression (Appendix Fig A6,
online only). There was no difference in outcomes between the
arms for the mesenchymal subtype with low HGF expression,
whereas patients with high HGF expression seemed to derive
beneﬁt from the addition of onartuzumab to bevacizumab. There
were no differences in outcomes for patients in the nonmesenchymal
subset with low HGF expression. The nonmesenchymal subset of
patients with high HGF expression was too small (n = 9) to ro-
bustly evaluate efﬁcacy.
MGMT Methylation Analysis
Methylation of MGMT is a well-known prognostic marker in
glioblastoma. Thus 110 patients (Ona + Bev, n = 56; Pla + Bev,
n = 54) were analyzed for MGMTmethylation status. Forty-seven
patients had methylated MGMT, 57 had unmethylated MGMT,
and six patients had unconﬁrmed MGMT status. Assessing the Pla
+ Bev arm only, patients had a worse outcome when treated with
Pla + Bev if they had unmethylated MGMT and a better prognosis
if they had methylated MGMT (PFS: HR, 3.19; 95% CI, 1.58 to
6.44; OS: HR, 3.39; 95% CI, 1.32 to 8.75; Appendix Fig A7, online
only).
Median PFS and OS were longer with Ona + Bev (n = 32)
compared with Pla + Bev (n = 25) in patients with unmethylated
MGMT (Fig 4); the median PFS was 4.2 v 2.8 months, respectively
(HR, 0.46; 95% CI, 0.25 to 0.84; P = .0108) and the median OS
was 10.9 v 7.5 months, respectively (HR, 0.53; 95% CI, 0.26 to
1.10; P = .0836). A numerically higher ORR was seen with Ona +
Bev compared with Pla + Bev in the unmethylated MGMT
subgroup (15.6% v 8.0%; P = .450). Among patients with
methylated MGMT, those treated with Ona + Bev (n = 21) had
shorter median PFS compared with patients treated with Pla +
Bev (n = 26; 2.8 v 6.4months, respectively; HR, 1.52; 95%CI, 0.75 to
3.08; P = .2440) and signiﬁcantly shorter median OS (7.7 months v
NR, respectively; HR, 3.18; 95% CI, 1.19 to 8.51; P = .0150).
Results of multivariable analyses of the HGF and MGMT
biomarkers are shown in Appendix Table A5 (online only). With
adjustment by the baseline characteristics, MGMT status and PCR
analysis of HGF still result in statistically signiﬁcant effects for PFS
and OS by MGMT methylation, and PFS by high or low HGF
expression. There was also a potentially predictive treatment effect
of Ona + Bev for patients with unmethylated MGMTor with high
HGF expression by PCR. The multivariable results were generally
consistent with the subgroup analyses.
Correlation between MGMT methylation and PFS beneﬁt
with bevacizumab in AVAglio was also investigated. No pre-
dictive inﬂuence of MGMT methylation status on PFS beneﬁt
Table 1. Baseline Patient Characteristics
Characteristic
Ona + Bev
(n = 64)
Pla + Bev
(n = 65)
Median age, years 57.0 55.0
Age , 50 years 18 (28.1) 17 (26.2)
Age $ 50 years 46 (71.9) 48 (73.8)
Sex
Male 44 (68.8) 39 (60.0)
Female 20 (31.3) 26 (40.0)
Karnofsky performance status
70%-80% 36 (56.3) 37 (56.9)
90%-100% 28 (43.8) 28 (43.1)
Race
Asian 3 (4.7) 0 (0.0)
White 59 (92.2) 64 (98.5)
Other 2 (3.1) 0 (0.0)
Multiple 0 (0.0) 1 (1.5)
Corticosteroid use at baseline 10 (15.6) 15 (23.1)
Prior surgery
Biopsy 5 (7.8) 2 (3.1)
Complete resection 32 (50.0) 38 (58.5)
Partial resection 26 (40.6) 23 (35.4)
Measurable disease at baseline* 54 (84.4) 59 (90.8)
Number of target lesions at baseline
# 1 39 (60.9) 47 (72.3)
. 1 15 (23.4) 12 (18.5)
Glioblastoma subtype n = 58 n = 61
Mesenchymal 27 (46.6) 29 (47.5)
Proneural 14 (24.1) 14 (23.0)
Proliferative 10 (17.2) 10 (16.4)
Unclassiﬁed 7 (12.1) 8 (13.1)
MET IHC score (50% staining cutoff)
0 52 (81.3) 53 (81.5)
1+ 4 (6.3) 9 (13.8)
2+ 3 (4.7) 1(1.5)
3+ 0 (0.0) 1 (1.5)
MET IHC (10% staining cutoff)
0 35 (54.7) 35 (53.8)
1+ 17 (26.6) 16 (24.6)
2+ 7 (10.9) 11 (16.9)
3+ 0 (0.0) 2 (3.1)
HGF PCR status n = 58 n = 61
Upper 25% 14 (24.1) 16 (26.2)
Lower 75% 44 (75.9) 45 (73.8)
HGF ISH score
0 16 (25.0) 17 (26.2)
1+ 21 (32.8) 25 (38.5)
2+ 16 (25.0) 18 (27.7)
3+ 4 (6.3) 3 (4.6)
MGMT methylation status n = 56 n = 54
Methylated 21 (37.5) 26 (48.1)
Unmethylated 32 (57.1) 25 (46.3)
Possible, weak methylation 3 (5.4) 3 (5.6)
IDH1 mutation status n = 58 n = 57
Mutation-positive 4 (6.9) 5 (8.8)
Wild-type 54 (93.1) 57 (91.2)
NOTE. Data presented as No. (%) unless otherwise noted.
Abbreviations: Bev, bevacizumab; HGF, hepatocyte growth factor; IDH1, iso-
citrate dehydrogenase 1; IHC, immunohistochemistry; ISH, in situ hybridization;
MET, mesenchymal-epithelial transition factor;MGMT, O6-methylguanine–DNA
methyltransferase; Ona, onartuzumab; PCR, polymerase chain reaction; Pla,
placebo.
*Conﬁrmation of measurable disease was not a protocol-deﬁned inclusion
criterion.
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with bevacizumab was observed (HR, 0.76 for methylated; HR,
0.56 for unmethylated).14
Safety
The median number of cycles for bevacizumab was ﬁve for
Ona + Bev and six for Pla + Bev; the median number of cycles for
onartuzumab was four and six for placebo. The most common
classes of adverse events (AEs; any grade) were general disorders
(70.8% Ona + Bev v 57.8% Pla + Bev), including peripheral edema
(44.6% v 14.1%), asthenia (24.6% v 21.9%), and fatigue (15.4% v
20.3%); and nervous system disorders (49.2% Ona + Bev v 75.0%
Pla + Bev), including headaches (15.4% v 23.4%). Grade $ 3 AEs
were reported in 38.5% (n = 25) of patients receiving Ona + Bev
and 35.9% (n = 23) of those receiving Pla + Bev, including nervous
system disorders (7.7% v 18.8%), vascular disorders (4.6% v
6.3%), and respiratory disorders (4.6% v 1.6%). Serious AEs were
reported in 30.8% and 29.7% of patients, respectively, for Ona +
Bev and Pla + Bev (Table 2). Grade 5 AEs were reported for two
patients receiving Ona + Bev (two cases of intestinal perforation)
and one patient receiving Pla + Bev (intracranial hemorrhage). AEs
(all grades) with a difference in incidence$ 10% between the arms
A B
Pla+Bev (n = 65)
median 2.9 months
Ona+Bev (n = 64)
median 3.9 months
HR (95% CI)
1.06 (0.72 to 1.56)
P = .7444 
No. at risk
Pla+Bev
Ona+Bev
65
64
31
35
17
19
8
7
0
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Time (months)
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0
0
Pla+Bev (N = 65) Ona+Bev (N = 64)
Baseline Risk
Factors
Total
n n Events
Median
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Fig 2. (A) Progression-free survival in the intent-to-treat population and (B) forest plot of progression-free survival subgroup analysis; (C) overall survival in the intent-to-
treat population and (D) forest plot of overall survival subgroup analysis. HR, hazard ratio; NE, non-evaluable; Ona + Bev, onartuzumab plus bevacizumab; Pla + Bev, placebo
plus bevacizumab; PS, performance status.
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were peripheral edema (44.6% Ona + Bev v 14.1% Pla + Bev),
hypertension (12.3% Ona + Bev v 32.8% Pla + Bev), and hypo-
albuminemia (12.3% Ona + Bev v 1.6% Pla + Bev).
DISCUSSION
Because recurrent glioblastoma has no standard treatment,28
novel treatment combinations are continually being investigated.
GO27819 evaluated the antiangiogenic agent bevacizumab plus the
anti-MET antibody onartuzumab in recurrent glioblastoma.
The GO27819 study reported a similar median PFS for Ona +
Bev relative to the Pla + Bev control. The median PFS with Ona +
Bev (3.9 months) was similar to that observed with bevacizumab
plus lomustine (4.0 months) in the BELOB study.12 The phase II
BRAIN study of bevacizumab plus irinotecan reported slightly
longer median PFS (5.6 months for bevacizumab plus irinotecan v
4.2 months for bevacizumab alone)7 than that reported in
GO27819. A median PFS of 3.6 months and a 6-month PFS rate of
18.8% was reported for a combination of bevacizumab with
temozolomide.13 Therefore, the PFS results in GO27819 are in
the range of those previously reported for bevacizumab-based
combination regimens for treatment of recurrent glioblastoma.
However, it is important to note that cross-trial comparisons
should be evaluated with caution, because there may be differences
in patient populations and neuroimaging assessment methods.
A planned efﬁcacy analysis by MET IHC status could not be
performed because of the low prevalence of MET-positive tumors,
a limitation of this study. This could have been avoided if the study
had been designed to enrich for MET-positive tumors, enrolling
patients until an adequate number of MET-positive samples were
available for analysis. The use of tissue from diagnosis, rather than
from the time of recurrence, to assess MET status may also be
considered a limitation.
In an exploratory biomarker analysis, HGF levels, MGMT
promoter methylation status, and glioblastoma subtype were
correlated with efﬁcacy outcomes. High HGF levels by PCR or ISH
seemed to be prognostic for worse OS and PFS, but potentially
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Fig 3. (A) Progression-free survival and (B) overall survival in the polymerase chain reaction levels of hepatocyte growth factor in the upper 25% subgroup; (C)
progression-free survival and(D) overall survival in the polymerase chain reaction levels of hepatocyte growth factor in the lower 75% subgroup. HR, hazard ratio; NE, non-
evaluable; Ona + Bev, onartuzumab plus bevacizumab; Pla + Bev, placebo plus bevacizumab.
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predictive of superior efﬁcacy with Ona + Bev compared with Pla +
Bev. HighHGF expression may indicate an aberrant MET pathway;
in gastric cancer models, expression of HGF correlates with MET
pathway activity and can predict efﬁcacy of anti-MET agents.29 In
hepatocellular carcinoma, circulating HGF levels correlate with
decreased survival in untreated patients.30
Analysis of HGF in the phase III AVAglio study of radio-
therapy, temozolomide plus bevacizumab or placebo in newly
diagnosed gliomas showed that the mesenchymal subtype was
associated with high HGF expression and reported that patients
with the mesenchymal subtype had longer OS than those with
other subtypes.16 In this onartuzumab study, HGF expression was
associated with the mesenchymal subtype; however, not all mes-
enchymal tumors expressed highHGF levels and the mesenchymal
phenotype was not associated with different outcomes compared
with other phenotypes, most likely as a result of the bevacizumab
backbone in both treatment arms.
Tumor-speciﬁc promoter methylation and silencing of
MGMT enhances the efﬁcacy of alkylating agents in tumor cells
because the cells are unable to efﬁciently repair damage induced
by these agents.26 The exploratory results in GO27819 suggest
that the lack of MGMTmethylation may be predictive for Ona +
Bev outcomes (PFS and OS) in glioblastoma, although the OS
results were not statistically signiﬁcant. However, in the AVAglio
study, no predictive inﬂuence of MGMT methylation status
was observed on bevacizumab efﬁcacy.14 MGMT silencing via
methylation allows alkylating agents to cause cell death by
crosslinking, thereby improving efﬁcacy of these agents.26 In the
absence of a direct biologic link betweenMGMTmethylation and
MET, other than a potentially additive effect on the apoptosis
pathway, it is notable that the treatment effect with unmethylated
MGMT was similar to the high HGF subgroup. Clearly, some
potent prognostic factors inﬂuence the pathogenesis of glio-
blastoma, which need to be considered in future trial designs.
Therefore, it is essential to appropriately size studies to enable
evaluation of exploratory hypotheses.
Although the biomarker data presented above are compelling
and should inform future trials targeting the MET pathway, their
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Fig 4. (A) Progression-free survival and (B) overall survival in the O6-methylguanine–DNA methyltransferase unmethylated subgroup; (C) progression-free survival and
(D) overall survival in the O6-methylguanine–DNAmethyltransferase methylated subgroup. HR, hazard ratio; NE, non-evaluable; Ona + Bev, onartuzumab plus bevacizumab;
Pla + Bev, placebo plus bevacizumab.
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exploratory nature and relatively small sample size make it dif-
ﬁcult to infer ﬁrm conclusions on the clinical utility of HGF
expression or MGMT methylation as predictive markers in
glioblastoma. Future prospective studies are necessary to validate
these results.
In conclucion, in the GO27819 trial, there was no evidence of
improved clinical beneﬁt with the addition of onartuzumab to
bevacizumab compared with bevacizumab plus placebo in ITT
patients with recurrent glioblastoma. However, exploratory bio-
marker analyses suggested that patients with high HGF expression
or unmethylated MGMT may beneﬁt from onartuzumab plus
bevacizumab.
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Appendix
Gene Expression Analysis on the NanoString Platform
Transcript levels in formalin-ﬁxed parafﬁn-embedded material were assayed on the NanoString gene expression platform
(NanoString Technologies, Seattle, WA), as described previously.16 Data preprocessing was performed using the NanoStringQCPro
Bioconductor package (version 1.0.1; http://www.bioconductor.org/packages/release/bioc/html/NanoStringQCPro.html) and the
R programming language (version 3.1; http://www.r-project.org). In brief, for each sample, unspeciﬁc background was estimated as
the mean expression across the negative-control probes and subtracted from the raw counts. Background-corrected counts were
log2 transformed and centered on the median expression of all probes designed to target endogenous transcripts (global median
normalization).
Gene Expression Subtype Classification
Subtype classiﬁcation was performed by assigning each sample to the reference centroid with the highest Pearson correlation
across the normalized expression of 31 classiﬁer genes,16 as described previously (Phillips HS, et al: Cancer Cell 9:157-173, 2006).
Samples without positive correlation to any reference centroid remained unclassiﬁed.
Differential Hepatocyte Growth Factor (HGF) Expression
Differential expression of HGF between glioblastoma subtypes was assessed by comparing normalized gene expression scores
on the log2 scale. Ninety-ﬁve percent CIs for mean HGF expression in each subgroup were estimated on the basis of the Student t
test distribution. P values were obtained by contrasting HGF expression in mesenchymal samples with those in each of the other
subtypes using a two-sided t test.
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Fig A1. Subpopulation treatment effect pattern plots for hepatocyte growth factor (HGF ). dCT, delta cycle threshold; HR, hazard ratio.
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Fig A2. Representative image of hepatocyte growth factor in situ hybridization staining.
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(D) nonmesenchymal subgroup. HR, hazard ratio; NE, non-evaluable; Ona + Bev, onartuzumab plus bevacizumab; Pla + Bev, placebo plus bevacizumab.
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Fig A4. (A) Progression-free survival and (B) overall surviva by NanoString expression of hepatocyte growth factor (HGF ) with standard of care and (C) progression-free
survival and (D) overall survival with standard of care plus bevacizumab in the Avastin in Glioblastoma (AVAglio) study. HR, hazard ratio.
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Fig A5. (A) Progression-free survival and (B) overall survival in the low hepatocyte growth factor by in situ hybridization subgroup; (C) progression-free survival and
(D) overall survival in the high hepatocyte growth factor by in situ hybridization subgroup. HR, hazard ratio; Ona + Bev, onartuzumab plus bevacizumab; Pla + Bev, placebo
plus bevacizumab.
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Fig A6. (A to D) Progression-free survival (PFS) and overall survival (OS) in mesenchymal and (E to H) nonmesenchymal subgroups stratiﬁed by hepatocyte growth factor
(HGF ) levels. HR, hazard ratio; NE, non-evaluable; Ona + Bev, onartuzumab plus bevacizumab; PCR, polymerase chain reaction; Pla + Bev, placebo plus bevacizumab.
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Fig A6. (Continued).
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Fig A7. (A) Progression-free survival and (B) overall survival by O6-methylguanine–DNA methyltransferase (MGMT ) methylation status in the placebo plus bevacizumab
arm. HR, hazard ratio; NE, non-evaluable.
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Table A4. High and Low Expression of Hepatocyte Growth Factor as Assessed by Polymerase Chain Reaction or In Situ Hybridization
Expression Level HGF by PCR, Upper 25% HGF by PCR, Lower 75% Total
HGF by ISH, 2+/3+ 19 (63.3) 22 (25.3) 41 (35.0)
HGF by ISH, 0/1+ 11 (36.7) 65 (74.7) 76 (65.0)
Total 30 (25.6) 87 (74.4) 117
NOTE. All values are expressed as no. (%).
Abbreviations: HGF, hepatocyte growth factor; ISH, in situ hybridization; PCR, polymerase chain reaction.
Table A1. Polymerase Chain Reaction Expression of Hepatocyte Growth Factor According to Glioblastoma Subtype in GO27819
Subtype No.
% Frequency in Sample
Population (n = 119) LSMEAN 95% CI P (ref: mesenchymal)
Mesenchymal 56 47.1 0.620710 0.4997 to 0.7417
Proliferative 20 16.8 0.198178 20.0025 to 0.3989 , .001
Proneural 28 23.5 0.336095 0.1665 to 0.5057 .0079
Unclassiﬁed 15 12.6 0.377946 0.1462 to 0.6097 .0684
Abbreviation: LSMEAN, least squares mean.
Table A2. NanoString Expression of Hepatocyte Growth Factor According to Glioblastoma Subtype in GO27819
Subtype No.
% Frequency in Sample
Population (n = 119) LSMEAN 95% CI P (ref: mesenchymal)
Mesenchymal 56 47.1 6.7279 6.3964 to 7.0593
Proliferative 20 16.8 5.3263 4.8257 to 5.8269 , .001
Proneural 28 23.5 5.9504 5.4167 to 6.4841 .0149
Unclassiﬁed 15 12.6 6.4224 5.9212 to 6.9235 .2946
NOTE. Hepatocyte growth factor expression is indicated in normalized log2 counts.
Abbreviation: LSMEAN, least squares mean.
Table A3. NanoString Expression of Hepatocyte Growth Factor According to Glioblastoma Subtype in Avastin in Glioblastoma (AVAglio) Trial
Subtype No.
% Frequency in Sample
Population (n = 339) LSMEAN 95% CI P (ref: mesenchymal)
Mesenchymal 139 41.0 6.3524 6.0206 to 6.6842
Proliferative 58 17.1 5.4113 4.8282 to 5.9944 .0062
Proneural 103 30.3 5.6896 5.2795 to 6.0997 .0136
Unclassiﬁed 39 11.5 6.7067 6.1210 to 7.2924 .2933
NOTE. Hepatocyte growth factor expression is indicated in normalized log2 counts.
Abbreviation: LSMEAN, least squares mean.
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Table A5. Multivariable Analysis of PCR Expression of Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Efﬁcacy Outcomes
Ona + Bev v Pla + Bev No. HR for Treatment 95% CI* P for Biomarker*
Treatment by Biomarker
Interaction P †
PFS 92 .0182 .173
MGMT 0.685 0.368 to 1.274
Unmethylated 1.369 0.648 to 2.890
Methylated
OS 92 .0409 .0276
MGMT 0.665 0.295 to 1.500
Unmethylated 3.007 1.095 to 8.257
Methylated
PFS 103 .0051 .0011
HGF by PCR 0.224 0.085 to 0.593
Upper 25% 1.397 0.851 to 2.295
Lower 75%
OS 103 .0618 .0077
HGF by PCR 0.201 0.041 to 0.984
Upper 25% 2.144 1.143 to 4.022
Lower 75%
NOTE. Model included Karnofsky performance status (70% to 80% v 90% to 100%); number of target lesions at baseline (1 v . 1); and glioblastoma subtype
(mesenchymal, proneural, proliferative, or unclassiﬁed), treatment, biomarker, and interaction term.
Abbreviations: HGF, hepatocyte growth factor; HR, hazard ratio;MGMT, O6-methylguanine–DNA methyltransferase; Ona + Bev, onartuzumab plus bevacizumab; OS,
overall survival; PCR, polymerase chain reaction; Pla + Bev, placebo plus bevacizumab; PFS, progression-free survival.
*Wald CI/test.
†Likelihood ratio test.
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